metformin has been researched along with Myotonic Dystrophy in 9 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Myotonic Dystrophy: Neuromuscular disorder characterized by PROGRESSIVE MUSCULAR ATROPHY; MYOTONIA, and various multisystem atrophies. Mild INTELLECTUAL DISABILITY may also occur. Abnormal TRINUCLEOTIDE REPEAT EXPANSION in the 3' UNTRANSLATED REGIONS of DMPK PROTEIN gene is associated with Myotonic Dystrophy 1. DNA REPEAT EXPANSION of zinc finger protein-9 gene intron is associated with Myotonic Dystrophy 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin, the well-known anti-diabetic drug, has been shown recently to improve the grip test performance of the DMSXL mouse model of myotonic dystrophy type 1." | 9.27 | Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. ( Arrouasse, R; Audureau, E; Baghdoyan, S; Bassez, G; Bhugaloo, H; Gourlay-Chu, ML; Hogrel, JY; Le Corvoisier, P; Peschanski, M, 2018) |
| "Metformin is a biguanide antidiabetic drug, with potential to delay aging at cellular and organismal levels." | 6.82 | Targeting Myotonic Dystrophy Type 1 with Metformin. ( García-Puga, M; López de Munain, A; Matheu, A; Saenz-Antoñanzas, A, 2022) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 5.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 5.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| "Metformin, the well-known anti-diabetic drug, has been shown recently to improve the grip test performance of the DMSXL mouse model of myotonic dystrophy type 1." | 5.27 | Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial. ( Arrouasse, R; Audureau, E; Baghdoyan, S; Bassez, G; Bhugaloo, H; Gourlay-Chu, ML; Hogrel, JY; Le Corvoisier, P; Peschanski, M, 2018) |
| "Metformin is a biguanide antidiabetic drug, with potential to delay aging at cellular and organismal levels." | 2.82 | Targeting Myotonic Dystrophy Type 1 with Metformin. ( García-Puga, M; López de Munain, A; Matheu, A; Saenz-Antoñanzas, A, 2022) |
| "Type 2 diabetes (T2D) and cancer have been shown to be part of the DM1 phenotype." | 1.56 | Diabetes, metformin and cancer risk in myotonic dystrophy type I. ( Alsaggaf, R; Amr, S; Gadalla, SM; Greene, MH; Pfeiffer, RM; St George, DMM; Wagner, KR; Wang, Y; Zhan, M, 2020) |
| "Metformin treatment is useful to improve insulin resistance in DM1." | 1.38 | [Glucose intolerance in myotonic dystrophy type 1]. ( Goto, T; Kon, S; Oyama, Y; Takada, H, 2012) |
| "It is important to choose the optimal treatment for DM in myotonic dystrophy, because the patients have hyperinsulinemia caused by specific mechanism and could not reduce the insulin resistance." | 1.33 | Low-dose metformin improves hyperglycaemia related to myotonic dystrophy. ( Komiya, I; Kouki, T; Nakachi, A; Takasu, N; Tamanaha, T; Tawata, M, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| García-Puga, M | 2 |
| Saenz-Antoñanzas, A | 2 |
| Matheu, A | 2 |
| López de Munain, A | 1 |
| Alsaggaf, R | 1 |
| Pfeiffer, RM | 1 |
| Wang, Y | 1 |
| St George, DMM | 1 |
| Zhan, M | 1 |
| Wagner, KR | 1 |
| Amr, S | 1 |
| Greene, MH | 1 |
| Gadalla, SM | 1 |
| Fernández-Torrón, R | 1 |
| Munain, AL | 1 |
| Bassez, G | 2 |
| Audureau, E | 2 |
| Hogrel, JY | 1 |
| Arrouasse, R | 1 |
| Baghdoyan, S | 1 |
| Bhugaloo, H | 1 |
| Gourlay-Chu, ML | 1 |
| Le Corvoisier, P | 1 |
| Peschanski, M | 2 |
| Carvalho, V | 1 |
| Martins, J | 1 |
| Takada, H | 1 |
| Oyama, Y | 1 |
| Kon, S | 1 |
| Goto, T | 1 |
| Kouki, T | 1 |
| Takasu, N | 1 |
| Nakachi, A | 1 |
| Tamanaha, T | 1 |
| Komiya, I | 1 |
| Tawata, M | 1 |
| Read, JA | 1 |
| Bearfield, P | 1 |
| Agarwal, B | 1 |
1 review available for metformin and Myotonic Dystrophy
| Article | Year |
|---|---|
Targeting Myotonic Dystrophy Type 1 with Metformin.
Topics: Humans; Hypoglycemic Agents; Metformin; Muscle Weakness; Myotonic Dystrophy; Phenotype | 2022 |
1 trial available for metformin and Myotonic Dystrophy
| Article | Year |
|---|---|
Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial.
Topics: Adult; Double-Blind Method; Female; Gait; Gait Disorders, Neurologic; Humans; Hypoglycemic Agents; M | 2018 |
7 other studies available for metformin and Myotonic Dystrophy
| Article | Year |
|---|---|
Diabetes, metformin and cancer risk in myotonic dystrophy type I.
Topics: Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Diabetes Mellitus, Type 1; Female; | 2020 |
Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin.
Topics: Adult; Aged; Energy Metabolism; Female; Fibroblasts; Humans; Hypoglycemic Agents; Leukocytes, Mononu | 2020 |
Could weight loss contribute to the improved mobility with metformin in patients with myotonic dystrophy type 1?
Topics: Humans; Metformin; Myotonic Dystrophy; Weight Loss | 2019 |
Reply: Could weight loss contribute to the improved mobility with metformin in patients with myotonic dystrophy type 1?
Topics: Humans; Metformin; Myotonic Dystrophy; Weight Loss | 2019 |
[Glucose intolerance in myotonic dystrophy type 1].
Topics: Glucose Intolerance; Humans; Insulin Resistance; Metformin; Myotonic Dystrophy | 2012 |
Low-dose metformin improves hyperglycaemia related to myotonic dystrophy.
Topics: Blood Glucose; C-Peptide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin | 2005 |
Glycaemic control in critically ill patients with myotonic dystrophy.
Topics: Critical Illness; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Myotonic Dystrophy | 2008 |